| Dr Gregory Burton Carlson, MD | |
|
68 School Road, Frisco, CO 80443 | |
| (970) 262-7400 | |
| Not Available |
| Full Name | Dr Gregory Burton Carlson |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 9 Years |
| Location | 68 School Road, Frisco, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609253632 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XX0005X | Orthopaedic Surgery - Sports Medicine | DR.0066858 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Anthony Summit Medical Center | Frisco, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centura Summit Orthopedics Llc | 6204210032 | 11 |
News Archive
The next generation of drugs will be designed on the basis of 3D protein models that scientists are creating. The Structural Genomics Consortium laboratory at Swedish medical university Karolinska Institutet has now made available the structure of PARP3, the four hundredth structure in this unique project to chart the body's proteins.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
The American Academy of Neurology (AAN), the world's largest professional association of neurologists, is releasing a position paper on how the practice of prescribing drugs to boost cognitive function, or memory and thinking abilities, in healthy children and teens is misguided.
The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
› Verified 3 days ago
| Entity Name | Summit Orthopedics Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750873667 PECOS PAC ID: 6507118486 Enrollment ID: O20181010000155 |
News Archive
The next generation of drugs will be designed on the basis of 3D protein models that scientists are creating. The Structural Genomics Consortium laboratory at Swedish medical university Karolinska Institutet has now made available the structure of PARP3, the four hundredth structure in this unique project to chart the body's proteins.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
The American Academy of Neurology (AAN), the world's largest professional association of neurologists, is releasing a position paper on how the practice of prescribing drugs to boost cognitive function, or memory and thinking abilities, in healthy children and teens is misguided.
The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
› Verified 3 days ago
| Entity Name | Centura Summit Orthopedics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942947916 PECOS PAC ID: 6204210032 Enrollment ID: O20220829001461 |
News Archive
The next generation of drugs will be designed on the basis of 3D protein models that scientists are creating. The Structural Genomics Consortium laboratory at Swedish medical university Karolinska Institutet has now made available the structure of PARP3, the four hundredth structure in this unique project to chart the body's proteins.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
The American Academy of Neurology (AAN), the world's largest professional association of neurologists, is releasing a position paper on how the practice of prescribing drugs to boost cognitive function, or memory and thinking abilities, in healthy children and teens is misguided.
The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gregory Burton Carlson, MD 68 School Road, Frisco, CO 80443 Ph: (970) 262-7400 | Dr Gregory Burton Carlson, MD 68 School Road, Frisco, CO 80443 Ph: (970) 262-7400 |
News Archive
The next generation of drugs will be designed on the basis of 3D protein models that scientists are creating. The Structural Genomics Consortium laboratory at Swedish medical university Karolinska Institutet has now made available the structure of PARP3, the four hundredth structure in this unique project to chart the body's proteins.
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.
The American Academy of Neurology (AAN), the world's largest professional association of neurologists, is releasing a position paper on how the practice of prescribing drugs to boost cognitive function, or memory and thinking abilities, in healthy children and teens is misguided.
The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
› Verified 3 days ago
Richard Williams, ATC, OTC Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 68 School Rd, Ste 100, Frisco, CO 80443 Phone: 970-262-7400 | |
Dr. Daniel Logan Worrell, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 68 School Rd, Ste 100, Frisco, CO 80443 Phone: 970-262-7400 Fax: 970-262-7401 | |
Peter C Janes, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 360 Peak One Drive, Ste 180, Frisco, CO 80443 Phone: 970-668-3633 Fax: 970-668-4406 | |
John T Joseph, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 360 Peak One Dr Ste 180, Frisco, CO 80443 Phone: 970-668-3633 Fax: 970-668-4406 | |
Dr. Rita Elizabeth Baumgartner, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 68 School Road, Ste 100, Frisco, CO 80443 Phone: 970-262-7400 | |
John E Gottlieb, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 360 Peak One Drive, Ste 180, Frisco, CO 80443 Phone: 970-668-3633 Fax: 970-668-4406 |